Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
Stock Information for Vaxart Inc.
Loading
Please wait while we load your information from QuoteMedia.